Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects

Alzheimer Disease and Associated Disorders

Volumn 27, Issue 3, 2013, Pages 278-286

  Imbimbo, Bruno P ^a   Frigerio, Enrico ^c   Breda, Massimo ^c   Fiorentini, Francesco ^c   Fernandez, Mercedes ^c   Sivilia, Sandra ^c   Giardino, Luciana ^c   Calzà, Laura ^c   Norris, Dottie ^a   Casula, Daniela ^a   Shenouda, Magdy ^b  

^a CHIESI FARMACEUTICI S P A   (Italy)

^b Iberica Clinical Research Center   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

secretase modulators; biomarkers; microglia

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CHF 5074; GAMMA SECRETASE INHIBITOR; PLACEBO; UNCLASSIFIED DRUG; 1-(3',4'-DICHLORO-2-FLUORO(1,1'-BIPHENYL)-4-YL)CYCLOPROPANECARBOXYLIC ACID; CYCLOPROPANE DERIVATIVE; ENZYME INHIBITOR; FLURBIPROFEN; NEUROPROTECTIVE AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABDOMINAL WALL DEFECT; ADULT; ALZHEIMER DISEASE; APHTHOUS STOMATITIS; AREA UNDER THE CURVE; BACKACHE; BLOOD SAMPLING; BODY MASS; CEREBROSPINAL FLUID; COGNITION; CONFERENCE PAPER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FLATULENCE; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MICROGLIA; MORNING DOSAGE; MUSCULOSKELETAL CHEST PAIN; MUSCULOSKELETAL PAIN; NAUSEA; NORMAL HUMAN; PARALLEL DESIGN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BLOOD; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; MIDDLE AGED; YOUNG ADULT;

ADULT; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FLURBIPROFEN; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; YOUNG ADULT;

EID: 84883295915     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e3182622ace     Document Type: Conference Paper

References (43)

1. Lesné S, Koh MT, Kotilinek L, et al. A specific amyloid-b protein assembly in the brain impairs memory. Nature. 2006;440:352-357.
2. Shankar GM, Li S, Mehta TH, et al. Amyloid-b protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837-842.
3. Olson RE, Albright. CF. Recent progress in the medicinal chemistry of g-secretase inhibitors. Curr Top Med Chem. 2008;8:17-33.
4. Lleo A. Activity of g-secretase on substrates other than APP. Curr Top Med Chem. 2008;8:9-16.
5. Lewis HD, Pérez Revuelta BI, Nadin A, et al. Catalytic sitedirected g-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and b-APP cleavages. Biochemistry. 2003;42:7580-7586.
6. Lathia JD, Mattson MP, Cheng A. Notch: from neural development to neurological disorders. J Neurochem. 2008;107: 1471-1481.
7. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Ab42 independently of cyclooxygenase activity. Nature. 2001;414:212-216.
8. Kukar T, Golde TE. Possible mechanisms of action of NSAIDs and related compounds that modulate g-secretase cleavage. Curr Top Med Chem. 2008;8:47-53.
9. Wilcock GK, Black SE, Hendrix SB, et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol. 2008;7:483-493.
10. Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer's disease: a randomized controlled trial. JAMA. 2009;302:2557-2564.
11. Peretto I, La Porta E. g-Secretase modulation and its promise for Alzheimer's disease: a medicinal chemistry perspective. Curr Top Med Chem. 2008;8:38-46.
12. Peretto I, Radaelli S, Parini C, et al. Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of bamyloid1-42 secretion. J Med Chem. 2005;48:5705-5720.
13. Imbimbo BP, Del Giudice E, Colavito D, et al. 1-(30,40-Dichloro-2- fluoro[1,10-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel g-secretase modulator, reduces brain b-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J Pharmacol Exp Ther. 2007;323:822-830.
14. Imbimbo BP, Del Giudice E, Cenacchi V, et al. In vitro and in vivo profiling of CHF5022 and CHF5074. Two b-amyloid1-42 lowering agents. Pharmacol Res. 2007;55:318-328.
15. Sarnico I, Lanzillotta A, Branca C, et al. The g-secretase modulator CHF5074 elicits neuroprotection and increases histone acetylation in primary cortical neurons exposed to oxygen glucose deprivation. Alzheimers Dement. 2011;7(suppl 1):S797. Abstract P4-269.
16. Imbimbo BP, Hutter-Paier B, Villetti G, et al. CHF5074, a novel g-secretase modulator, attenuates brain b-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br J Pharmacol. 2009;156:982-993.
17. Imbimbo BP, Giardino L, Sivilia S, et al. CHF5074, a novel g-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis. 2010;20:159-173.
18. Balducci C, Mehdawy B, Mare L, et al. The g-secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice. J Alzheimers Dis. 2011;24:799-816.
19. Tan J, Town T, Paris D, et al. Microglial activation resulting from CD40-CD40L interaction after b-amyloid stimulation. Science. 1999;286:2352-2355.
20. Desideri G, Cipollone F, Necozione S, et al. Enhanced soluble CD40 ligand and Alzheimer's disease: evidence of a possible pathogenetic role. Neurobiol Aging. 2008;29:348-356.
21. Buchhave P, Janciauskiene S, Zetterberg H, et al. Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease. Neurosci Lett. 2009;450:56-59.
22. Ait-ghezala G, Abdullah L, Volmar CH, et al. Diagnostic utility of APOE, soluble CD40, CD40L, and Ab1-40 levels in plasma in Alzheimer's disease. Cytokine. 2008;44:283-287.
23. Calingasan NY, Erdely HA, Altar CA. Identification of CD40 ligand in Alzheimer's disease and in animal models of Alzheimer's disease and brain injury. Neurobiol Aging. 2002;23:31-39.
24. Sivilia S, Lorenzini L, Giuliani A, et al. Chronic administration of CHF5074, a novel g-secretase modulator, prevents brain neurodegeneration in aged Alzheimer's disease transgenic mice. Alzheimers Dement. 2011;7(suppl 1):S520. Abstract P3-016.
25. Varvel NH, Bhaskar K, Kounnas MZ, et al. NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J Clin Invest. 2009;119:3692-3702.
26. Galasko D, Montine TJ. Biomarkers of oxidative damage and inflammation in Alzheimer's disease. BiomarkMed. 2010;4:27-36.
27. Schuitemaker A, van der Doef TF, Boellaard R, et al. Microglial activation in healthy aging. Neurobiol Aging. 2012;33:1067-1072.
28. Wiley CA, Lopresti BJ, Venneti S, et al. Carbon 11-labeled Pittsburgh compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol. 2009;66:60-67.
29. Frigerio E, Breda M. Bioanalytical and toxicokinetic report for the quantification of CHF 5074 in brain tissues and cerebrospinal fluid for the study CHF 5074: 4 week oral toxicity study in dogs followed by a 4 week recovery period. Report 0068-2009-R. Accelera S.r.l., Nerviano, Italy. May 21, 2009.
30. Schor NF. What the halted phase III g-secretase inhibitor trial may (or may not) be telling us. Ann Neurol. 2011;69:237-239.
31. Salloway S, Coric V, Brody M, et al. Safety and tolerability of BMS-708163 in a phase II study in mild-to-moderate Alzheimer's disease. Alzheimers Dement. 2011;7(suppl 1): S692. Abstract O4-06-08.
32. Kim J, Onstead L, Randle S, et al. Ab40 inhibits amyloid deposition in vivo. J Neurosci. 2007;27:627-633.
33. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Ab42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008; 372:216-223.
34. Galasko DR, Van Dyck C, Sabbagh M, et al. A randomized trial of a RAGE-Ab interactions in patients with mild to moderate AD. J Nutr Health Aging. 2011;15:S9. Abstract O12.
35. Castellani RJ, Lee HG, Zhu X, et al. Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol. 2008; 67:523-531.
36. Castellani RJ, Lee HG, Siedlak SL, et al. Reexamining Alzheimers disease: evidence for a protective role for amyloid-b protein precursor and amyloid-beta. J Alzheimers Dis. 2009;18:447-452.
37. Tampellini D, Rahman N, Gallo EF, et al. Synaptic activity reduces intraneuronal Ab, promotes APP transport to synapses, and protects against Ab related synaptic alterations. J Neurosci. 2009;29:9704-9713.
38. Abramov E, Dolev I, Fogel H, et al. Amyloid-b as a positive endogenous regulator of release probability at hippocampal synapses. Nature Neurosci. 2009;12:1567-1576.
39. Puzzo D, Privitera L, Leznik E, et al. Picomolar amyloid-b positively modulates synaptic plasticity and memory in hippocampus. J Neurosci. 2008;28:14537-14545.
40. Morley JE, Farr SA, Banks WA, et al. A physiological role for amyloid-b protein: enhancement of learning and memory. J Alzheimers Dis. 2010;19:441-449.
41. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509-1517.
42. Struble RG, Ala T, Patrylo PR, et al. Is brain amyloid production a cause or a result of dementia of the Alzheimer's type? J Alzheimers Dis. 2010;22:393-399.
43. Glass DJ, Arnold SE. Some evolutionary perspectives on Alzheimer's disease pathogenesis and pathology. Alzheimers Dement. 2011. doi:10.1016/j.jalz.2011.05.2408. [Epub ahead of print].